Search
for

    Learn

    5 / 7 results

      learn Tofacitinib

      a JAK inhibitor for alopecia areata and other autoimmune conditions
      [object Object]

      learn Baricitinib

      JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

      learn Metformin

      diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties

    Research

    5 / 1000+ results

    Community Join

    5 / 188 results
      If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      in Research  830 upvotes 5 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
      [object Object]

      community Hair loss 30F - thoughts on red light therapy vs min/fin?

      in Female  6 upvotes 4 months ago
      The conversation discusses hair loss treatments for a 30-year-old female, comparing red light therapy with minoxidil and finasteride. Concerns about hormonal impact and potential pregnancy are raised, with suggestions to consider spironolactone and microneedling, while emphasizing the importance of consulting a dermatologist.

      community He used Dutasteride for 20 years. Interview

      in Treatment  109 upvotes 2 months ago
      Dutasteride has been used for 20 years with some hair thickness improvement but no dramatic regrowth. The user also experimented with minoxidil, tretinoin, and peptides like BPC 157 for potential benefits in hair density and quality.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  38 upvotes 2 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.